HämolyseMarkerprofil

HämolyseMarkerprofil refers to a panel of laboratory tests used to detect and quantify hemolysis, the premature destruction of red blood cells. This process can occur in vivo, meaning within the body, or ex vivo, meaning outside the body during sample collection or processing. Elevated levels of certain substances released from red blood cells indicate hemolysis.

Common markers included in a HämolyseMarkerprofil are free hemoglobin in plasma or serum, lactate dehydrogenase (LDH), aspartate aminotransferase (AST), and bilirubin. Free hemoglobin is a direct indicator of red blood cell breakdown. LDH and AST are enzymes found in high concentrations within red blood cells, and their release into the bloodstream signifies cellular damage. Bilirubin, a breakdown product of heme, can also be elevated if hemolysis is significant.

The interpretation of a HämolyseMarkerprofil is crucial for diagnosing various medical conditions. In vivo hemolysis can be caused by autoimmune hemolytic anemia, drug-induced hemolysis, mechanical heart valve dysfunction, or infections. Ex vivo hemolysis, often referred to as a pseudohämolyse, can occur due to difficult blood draws, improper sample handling, or prolonged storage. Differentiating between these causes is important for accurate diagnosis and appropriate treatment. If ex vivo hemolysis is suspected, the laboratory may reject the sample or redraw it. A HämolyseMarkerprofil helps clinicians assess the extent of red blood cell destruction and investigate its underlying cause.